[加巴喷丁类药物的超说明书用药：是否需要减药策略？]

[Off-label use of gabapentinoid drugs: is it necessary a deprescription strategy?].

作者信息

Echeverría Gorriti Amaya, Alzueta Istúriz Natalia, García González Patricia, Fernández González Julen, Sanz Álvarez Lorea, Garjón Parra Javier

机构信息

Subdirección de Farmacia y Prestaciones, Servicio Navarro de Salud-Osasunbidea, Pamplona, España; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, España.

出版信息

Gac Sanit. 2022 Dec 22;37:102283. doi: 10.1016/j.gaceta.2022.102283. eCollection 2023.

DOI:10.1016/j.gaceta.2022.102283

PMID:36565565

Abstract

OBJECTIVE

To evaluate gabapentin and pregabalin treatment adequacy to label indications, to analyze off-label use and to identify patients at high risk of respiratory depression.

METHOD

An observational, retrospective study was performed. It included patients treated with pregabalin and gabapentin during 2020 in Navarre.

RESULTS

A total of 9778 patients were treated with gabapentin or pregabalin during the first two months of 2020. In 56% of the cases, gabapentinoids were prescribed for off-label uses. Sixty percent of patients were taking at least one central nervous system (CNS) depressant drug concomitantly, 33% of them opioids, 20% of them combined opioids with CNS depressants and 4% of them at least one systemic antihistamine. In addition, 11% of the patients had a diagnosis of asthma or COPD. Prevalences remained constant along the year.

CONCLUSIONS

It is necessary to implement a gabapentinoid deprescription strategy to improve its use and reduce safety problems.

摘要

目的

评估加巴喷丁和普瑞巴林的治疗是否符合药品标签适应证，分析超适应证用药情况，并识别呼吸抑制高危患者。

方法

进行了一项观察性回顾性研究。研究对象为2020年在纳瓦拉接受普瑞巴林和加巴喷丁治疗的患者。

结果

2020年的前两个月，共有9778例患者接受了加巴喷丁或普瑞巴林治疗。在56%的病例中，加巴喷丁类药物的处方为超适应证用药。60%的患者同时服用至少一种中枢神经系统（CNS）抑制药物，其中33%服用阿片类药物，20%将阿片类药物与CNS抑制药物联合使用，4%服用至少一种全身性抗组胺药。此外，11%的患者被诊断患有哮喘或慢性阻塞性肺疾病（COPD）。全年患病率保持不变。